Noema Pharma
Founded 2019 · 35 employees on LinkedIn · 11 known investors
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs. The company works with patients, caregivers, and healthcare professionals throughout discovery and clinical development.
Founders & leadership
IL
Ilise LombardoChief Executive Officer
VK
Volker KnappertzExecutive Vice President of Research & Development
MS
Michael SamarChief Financial Officer
RL
Rob LasserChief Medical Officer
Investors · 11
BioMedPartnersBasel · $648K – $6.5M
Jeito CapitalParis
Roche Venture FundBasel · $648K – $3.2M
Sofinnova PartnersParis · $540K – $27M
EQTreported · 2 sourcesNew York
EQT Life Sciencesreported · 2 sourcesLuxembourg · $11M – $66M
Forbionreported · 2 sourcesNaarden
Gilde Healthcarereported · 2 sourcesUtrecht · $1.1M – $55M
InvusreportedNew York
Also in the syndicate · 2
Polaris PartnersUPMC Enterprises
Funding
SEC filings, press & company announcements- Undisclosed amountextension of its series B funding roundNov 2025
EQT Life Sciences (lead), EQT, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, Sofinnova Partners, UPMC Enterprises
Source ↗ - Undisclosed amountSeries BDec 2024Source ↗
- $112MSeries BMar 2023 · 3 sources
Forbion (lead), Jeito Capital (lead), Gilde Healthcare, Invus, Polaris Partners, Sofinnova Partners, UPMC Enterprises
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 5
by search overlap
NMD Pharma5 shared keywordsNMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions. Its lead candidate, ignaseclant (NMD670), is in clinical development for Charcot-Marie-Tooth disease, generalized myasthenia gravis, and spinal muscular atrophy.</parameter>
<parameter name="founders">[]
Forbion4 shared keywordsForbion is a global venture capital firm that invests in biotech innovations and sustainable solutions focused on human and planetary health. It integrates ESG principles into its investments, targeting patient impact, societal benefits, and sustainability.
Doximity3 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Veeva3 shared keywordsVeeva Clinical Platform is a cloud-based suite of connected applications for running clinical trials, covering clinical operations, clinical data, research sites, and patients. It serves biopharma sponsors, clinical research sites, and patients across trial management, data capture, and disclosures.
Nrxpharma3 shared keywordsNRx Pharmaceuticals develops medicines for people with unmet medical needs, focused on making untreatable diseases treatable. It operates in the pharmaceutical and biotech industry.
Companies competing with Noema Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Noema Pharma do?
- Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs. The company works with patients, caregivers, and healthcare professionals throughout discovery and clinical development.
- Who are Noema Pharma's investors?
- Noema Pharma's investors include BioMedPartners, Jeito Capital, Roche Venture Fund, Sofinnova Partners, EQT, EQT Life Sciences, Forbion, Gilde Healthcare and 1 more.